The cost of adverse drug reactions

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 3, 2003, Pages 319-326

  Gautier, Sophie ^b   Bachelet, Hélène ^b   Bordet, Régis ^b   Caron, Jacques ^a  

^a Faculté de Médicine   (France)

^b UNIV LILLE   (France)

Author keywords

Adverse drug reaction; Cost prevention; Evaluation

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CARDIOVASCULAR DISEASE; CONTROL STRATEGY; DRUG COST; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; ECONOMIC EVALUATION; EDUCATION PROGRAM; GOOD CLINICAL PRACTICE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH PROGRAM; HIGH RISK POPULATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MEDICAL SPECIALIST; PHARMACIST; PROFESSIONAL PRACTICE; REVIEW; SKIN DISEASE;

EID: 0344255717     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.3.319     Document Type: Review

References (56)

1. LEAPE LL, BRENNAN TA, LAIRD N et al.: The nature of adverse events in hospitalized patients. N. Engl. J. Med. (1991) 324(6):377-384.
2. International drug monitoring: the role of the hospital. World Health Organization, Geneva, Switzerland (1984). WHO publication DEM/NC/84.153 (E).
3. LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA (1998) 279(15):1200-1205.
4. TALLEY RB, LAVENTURIER MF: Drug-induced illness.JAMA (1974) 229:1043-1048.
5. PORTER J, JICK H: Drug-related deaths among medical inpatients. JAMA (1977) 237:879-881.
6. JOHNSON JA, BOOTMAN JL: Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am. J. Health Syst. Pharm. (1997) 54:554-558.
7. LUMLEY CE, WALKER SR, HALL GC: The under-reporting of adverse drug reactions seen in general practice. Pharma. Med. (1986) 1:205-212.
8. CHEW R: OHE Compendium of Health Statistics 9th edn. Office of Health Economics, London, UK (1995).
9. MUNASINGHE TM, SINGER DRJ: Costs and prevention of adverse drug reactions. Eur. J. Intern. Med. (2001) 12:403-405.
10. GOETTLER M, SCHNEEWEISS S, HASFORD J: Adverse drug reaction monitoring - cost and benefit considerations part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol. Drug Saf. (1997) 6:S79-S90.
11. EVANS RS, CLASSEN DC, STEVENS LE et al.: Using a hospital information system to assess the effects of adverse drug events. In: Proceedings from the Seventeenth Annual Symposium on Computer Applications in Medical Care 1993. Safran C (Ed.) McGraw-Hill, Inc., NY, USA (1993):161-165.
12. SCHNEIDER PJ, GIFT MG, LEE YP, ROTHERMICH EA, SILL BE: Cost of medication-related problems at a university hospital. Am. J. Health Syst. Pharm. (1995) 52:2415-2418.
13. MOORE N, BRIFFAUT C, NOBLET C, NORMAND CA, THUILLEZ C: Indirect drug-related costs. Lancet (1995) 345:588-589.
14. CLASSEN DC, PESTOTNIK SL, EVANS RS, LLOYD JF, BURKE JP: Adverse drug events in hospitalized patients. excess length of stay, extra costs, and attributable mortality. JAMA (1997) 277(4):301-306.
15. BATES DW, SPELL N, CULLEN DJ et al.: The costs of adverse drug events in hospitalized patients. JAMA (1997) 277(4):307-311.
16. WASSERFALLEN JB, LIVIO F, BUCLIN T, TILLETL, YERSIN B, BIOLLAZ J: Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur. J. Intern. Med. (2001) 12:442-447.
17. DETOURNAY B, FAGNANI F, POUYANNE P et al.: Coût des hospitalisations pour effet indésirable médicamenteux. Thérapie (2000) 55:137-139.
18. FAICH GA, KNAPP D, DREIS M, TURNER W. National adverse drug reaction surveillance: 1985. JAMA (1987) 257(15):2068-2070.
19. DUKES MNG: Economic costs of adverse drug reactions. Pharmaroeconomics (1992) 1(3):153-154.
20. EISENBERG JM: Clinical economics. A guide to the economic analysis of clinial practices.JAMA (1989) 262(20):2879-2886.
21. SENST BL, ACHUSIM LE, GENEST RP et al.: Practical approach to determining costs and frequency of adverse drug events in a healthcare network. Am. J. Health Syst. Pharm. (2001) 58:1126-1132.
22. EVANS RS, PESTOTNIK SL, CLASSEN DC, HORN SD, BASS SB, BURKE JP: Preventing adverse drug events in hospitalized patients. Ann. Pharmacother. (1994) 28:523-527.
23. DARTNELL JGA, ANDERSON RP, CHOHAN V et al.: Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med. J. Aust. (1996) 164:659-662.
24. DORMANN H, MUTH-SELBACH U, KREBS S et al.: Incidence and costs of adverse drug reactions during hospitalisation. Computerised monitoring versus stimulated spontaneous reporting. Drug Saf. (2000) 22(2):161-168.
25. MOORE N, LECOINTRE D, NOBLET C, MABILLE M: Frequency and cost of serious adverse drug reactions in a department of general medicine. Br. J. Clin. Pharmacol. (1998) 45:301-308.
26. LAGNAOUI R, MOORE N, FACH J, LONGY-BOURSIER M, BEGAUD B: Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur. J. Clin. Pharmacol. (2000) 55:181-186.
27. SUH DC, WOODALL BS, SHIN SK, HERMES-DE SANTIS ER: Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann. Pharmacother. (2000) 34:1373-1379.
28. LAPEYRE-MESTRE M, GARY J, MACHELARD-ROUMAGNAC M, BONHOMME C, BUGAT R, MONTASTRUC JL: Incidence and cost of adverse drug reactions in a French cancer institute. Eur. J. Clin. Pharmacol. (1997) 53:19-22.
29. BORDET R, GAUTIER S, LE LOUET H, DUPUIS B, CARON J: Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur. J. Clin. Pharmacol. (2001) 56:935-941.
30. WHITE TJ, ARAKELIAN A, RHO JP: Counting the costs of drug-related adverse events. Pharmacoeconomics (1999) 15(5):445-458.
31. KARCH FE, LASAGNA L: Adverse drug reactions. A critical review-JAMA (1975) 234(12):1236-1241.
32. CLASSEN DC, PESTOTNIK SL, EVANS S, BURKE JP: Computerized surveillance of adverse drug events in hospital patients. JAMA (1991) 266(20):2847-2851.
33. BATES DW, CULLEN DJ, LAIRD N et al.: Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA (1995) 274(1):29-34.
34. BRENNAN TA, HEBERT L, LAIRD NM et al.: Hospital characteristics associated with adverse events and substandard care. JAMA (1991) 265:3265-3269.
35. JHA AK, KUPERMAN GJ, RITTENBERG E, TEICH JM, BATES DW. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol. Drug Saf. (2001) 10:113-119.
36. BERRY LL, SEGAL R, SHERRIN TP, FUDGE KA: Sensitivity and specificity of three methods of detecting adverse drug reactions. Am. J. Hosp. Pharm. (1988) 45:1534-1539.
37. VAN DEN BEMT PMLA, EGBERTS ACG, LENDERINK AW et al.: Adverse drug events in hospitalized patients. A comparison of doctors, nurses and patients as sources of reports. Eur. J. Clin. Pharmacol. (1999) 55:155-158.
38. THURMANN PA: Methods and systems to detect adverse drug reactions in hospitals. Drug Saf. (2001) 24(13):961-968.
39. EDWARDS IR, ARONSON JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 356:1255-1259.
40. BEGAUD B, EVREUX JC, JOUGLARD J, LAGIER G: Imputabilité des effets inattendus on toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie (1985) 40:111-118.
41. PEARSON TF, PITTMAN DG, LONGLEY JM, GRAPES T, VIGLIOTTI DJ, MULLIS SR: Factors associated with preventable adverse drug reactions. Am. J. Hosp. Pharm. (1994) 51:2268-2272.
42. PETERSEN LA, BRENNAN TA, O'NEIL AC, COOK EF, LEE TH: Does house-staff discontinuity of care increase the risk for preventable adverse events? Ann. Intern. (1994) 121:866-872.
43. IMBS JL, PLETAN Y, SPRIET A: Evaluation de la iatrogénèse médicamenteuse évitable: méthodologie. Thérapie (1998) 53:365-370.
44. HALEY RW, SCHABERG DR, VON ALLMEN SD, MCGOWAN JE Jr: Estimating the extra charges and prolongation of hospitalization due to nosocomial infections: a comparison of methods. J. Infect. Dis. (1980) 141(2):248-257.
45. CRAMER JA: Relationship between medication compliance and medical outcomes. Am. J. Health Syst. Pharm. (1995) 52(Suppl. 3):S27-S29.
46. LEAPE LL, BATES DW, CULLEN DJ et al.: Systems analysis of adverse drug events. JAMA (1995) 274:35-43.
47. POUYANNE P, HARAMBURU F, IMBS JL, BEGAUD B: Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. Br. Med. J. (2000) 320:1036.
48. LOBAS NH, LEPINSKI PW, ABRAMOWITZ PW: Effects of pharmaceutical care on medication cost and quality of patient care in an ambulatory-care clinic. Am. J. Hosp. Pharm. (1992) 49:1681-1688.
49. LEAPE LL, CULLEN DJ, CLAPP MD et al.: Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA (1999) 282:267-270.
50. CRANE VS: New perspectives on preventing medication errors and adverse drug events. Am. J. Health Syst. Pharm. (2000) 57:690-697.
51. BERINGER PM, WONG-BERINGER A, RHO JP: Economic aspects of antibacterial adverse effects. Pharmacoeconomics (1998) 13:35-49.
52. PIRMOHAMED M, BRECKENRIDGE AM, KITTERINGHAM NR, PARK BK: Fortnightly review. Adverse drug reactions. Br. Med. J. (1998) 316:1295-1298.
53. MEYBOOM RHB, EGBERTS ACG, EDWARDS IR, HEKSTER YA, DE KONING FHP, GRIBNAU FWJ: Principles of signal detection in pharmacovigilance. Drug Saf. (1997) 16:355-365.
54. PIQUET C, MALLARET M, BONTEMPS H, FABRE M, SARROT-REYNAUD F, IMBERT B: Effets indésirables et erreurs de médication: incidence et rôle de l'organisation du circuit du médicament. Thérapie (1999) 54:49-53.
55. MOORE TJ, PSATY BM, FURBERG CD: Time to act on drug safety. JAMA (1998) 279(19):1571-1573.
56. LEVY M, AZAZ-LIVSHITS T, SADAN B, SHALIT M, GEISSLINGER G, BRUNE K: Computerized surveillance of adverse drug reactions in hospital: implementation. Eur. J. Clin. Pharmacol. (1999) 54:887-892.